Q-omics provides the consensus-scored P2RX5 profile across patient tissues and cancer cell-line models. P2RX5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, P2RX5 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, P2RX5 RNA expression shows 16,045 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUAD, and THYM as cancer lineages where P2RX5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for P2RX5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes P2RX5 survival associations across molecular data types. P2RX5 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible P2RX5 RNA expression–survival associations across cancer types. High P2RX5 expression shows unfavorable associations in KIRC, ACC and UVM, but favorable associations in SKCM, OV and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for P2RX5 RNA expression.
This table summarizes P2RX5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for P2RX5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. P2RX5 shows higher tumor expression in LUAD, KIRC, HNSC, STAD, BRCA and UCEC. The LUAD box plot shows higher P2RX5 RNA expression in tumor versus normal tissue (log2 FC = +0.926, t-test p < 0.001).
This table shows molecular features associated with P2RX5 in patient tissues and cancer cell lines. In patient samples, P2RX5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, P2RX5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
